{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:56:33Z","timestamp":1793148993131,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-026-00741-0","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T13:44:34Z","timestamp":1774014274000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Semaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Basile","family":"Njei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan A.","family":"Al-Ajlouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dam Nsoh","family":"Tanih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrick Sidney","family":"Kanmounye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarpong","family":"Boateng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled W.","family":"Halwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy Loic","family":"Nguefang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"issue":"1","key":"741_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"JV Lazarus","year":"2022","unstructured":"Lazarus JV, Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Reviews Gastroenterol Hepatol. 2022;19(1):60\u201378.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"1","key":"741_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cgh.2023.05.019","volume":"22","author":"JH Koh","year":"2024","unstructured":"Koh JH, Ng CH, Nah B, et al. NASH is the leading cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2024;22(1):197\u20139. e3.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"741_CR3","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","volume":"17","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748\u201355. e3.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"741_CR4","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","volume":"113","author":"M Noureddin","year":"2018","unstructured":"Noureddin M, Vipani A, Bresee C, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Official J Am Coll Gastroenterology| ACG. 2018;113(11):1649\u201359.","journal-title":"Official J Am Coll Gastroenterology| ACG"},{"issue":"1","key":"741_CR5","doi-asserted-by":"publisher","first-page":"e0352","DOI":"10.1097\/HC9.0000000000000352","volume":"8","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Stepanova M, Al Shabeeb R, et al. The changing epidemiology of adult liver transplantation in the United States in 2013\u20132022: The dominance of metabolic dysfunction\u2013associated steatotic liver disease and alcohol-associated liver disease. Hepatol Commun. 2024;8(1):e0352.","journal-title":"Hepatol Commun"},{"issue":"1","key":"741_CR6","doi-asserted-by":"publisher","first-page":"e2454707","DOI":"10.1001\/jamanetworkopen.2024.54707","volume":"8","author":"P Le","year":"2025","unstructured":"Le P, Tatar M, Dasarathy S, et al. Estimated Burden of Metabolic Dysfunction\u2013Associated Steatotic Liver Disease in US Adults, 2020 to 2050. JAMA Netw Open. 2025;8(1):e2454707\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"741_CR7","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/hep.30254","volume":"69","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Tampi R, Priyadarshini M, Nader F, Younossi IM, Racila A. Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States. Hepatology. 2019;69(2):564\u201372.","journal-title":"Hepatology"},{"issue":"2","key":"741_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2337\/dc19-1113","volume":"43","author":"ZM Younossi","year":"2020","unstructured":"Younossi ZM, Tampi RP, Racila A, et al. Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the US. Diabetes Care. 2020;43(2):283\u20139.","journal-title":"Diabetes Care"},{"key":"741_CR9","unstructured":"Klein HE. Global MASH burden projected to double costs, raise mortality without intervention. Am J Manag Care. 2025."},{"issue":"6","key":"741_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497\u2013509.","journal-title":"N Engl J Med"},{"issue":"21","key":"741_CR11","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399.","journal-title":"N Engl J Med"},{"issue":"6","key":"741_CR12","doi-asserted-by":"publisher","first-page":"e2517122","DOI":"10.1001\/jamanetworkopen.2025.17122","volume":"8","author":"P Le","year":"2025","unstructured":"Le P, Dasarathy S, Herman WH, et al. Value-based pricing of resmetirom for metabolic dysfunction\u2013associated steatotic liver disease. JAMA Netw Open. 2025;8(6):e2517122.","journal-title":"JAMA Netw Open"},{"issue":"24","key":"741_CR13","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"741_CR14","doi-asserted-by":"publisher","first-page":"e16119","DOI":"10.1111\/liv.16119","volume":"45","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Paik JM, Henry L, Stepanova M, Nader F. Pharmaco-economic assessment of screening strategies for high\u2010risk MASLD in primary care. Liver Int. 2025;45(4):e16119.","journal-title":"Liver Int"},{"key":"741_CR15","unstructured":"Index CP. US Bureau of labor statistics. 2011."},{"issue":"1","key":"741_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/13696998.2025.2459529","volume":"28","author":"P McEwan","year":"2025","unstructured":"McEwan P, B\u00f8g M, Faurby M, et al. Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes. J Med Econ. 2025;28(1):268\u201378.","journal-title":"J Med Econ"},{"issue":"11","key":"741_CR17","doi-asserted-by":"publisher","first-page":"e2542750","DOI":"10.1001\/jamanetworkopen.2025.42750","volume":"8","author":"JV Lazarus","year":"2025","unstructured":"Lazarus JV, Agirre-Garrido L, D\u00edaz LA, et al. Cost-effectiveness of MASH diagnosis and management approaches among those with type 2 diabetes. JAMA Netw Open. 2025;8(11):e2542750.","journal-title":"JAMA Netw Open"},{"issue":"9\u2013a Suppl","key":"741_CR18","first-page":"S1","volume":"30","author":"B Flavin","year":"2024","unstructured":"Flavin B. Nonalcoholic steatohepatitis\/metabolic dysfunction\u2013associated steatohepatitis emerging market: Preparing managed care for early intervention, equitable access, and integrating the patient perspective. J Managed Care Specialty Pharm. 2024;30(9\u2013a Suppl):S1\u201313.","journal-title":"J Managed Care Specialty Pharm"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00741-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00741-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00741-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:36:20Z","timestamp":1777422980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-026-00741-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["741"],"URL":"https:\/\/doi.org\/10.1186\/s12962-026-00741-0","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"20 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"During the preparation of this manuscript, the authors used ChatGPT (OpenAI) to assist with language editing and improvement of clarity and grammar. After using this tool, the authors critically reviewed and edited all content, verified its accuracy, and take full responsibility for the integrity and content of the published article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the manuscript preparation process"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}